DOSE AND TIME-DEPENDENT EFFECTS OF STATINS ON GLYCEMIC STATUS AND THEIR ASSOCIATION WITH NEW ONSET DIABETES MELLITUS

摘要

of new-onset diabetes mellitus (NODM).Methods: The study was conducted for a period of 2 months from July 2014 to August 2014. In this cross-sectional observational study, non-diabeticsubjects, who were on statin therapy for more than 2 months were recruited. Participants having previous records of results of diagnostic tests forblood glucose levels (before starting statin therapy) such as random blood sugar (RBS), fasting blood sugar, and glycated hemoglobin (HbA1c) valueswithin normal range were included in the study and that values were taken as baseline value. Then another measurement of the same tests repeatedwhen they enrolled into the study.Results and Discussion: Of 22 subjects, 3 subjects were on rosuvastatin and the remaining 19 were on atorvastatin. Among the 22 subjects, 17 hadsymptoms of hyperglycemia such as polyuria, polydipsia, polyphagia, etc. after starting treatment with statins. It has been found that treatment withstatins increases the risk of new NODM (27%) and there was a significant rise in the mean red blue and green (RBG) levels after therapy. Furthermore,there was a statistically significant rise in HbA1c values as the doses were increased. The duration of treatment and the body mass index and the typeof statin have not significantly influenced the HbA1c values.Conclusion: The values of statins in cardiovascular disorders have been clearly established and accepted. Their benefit is undeniable; however, theyneed to be taken with caution and care. Physicians should be aware of this adverse drug reaction due to statin therapy and they should monitor theglycemic control status of the patients during their regular follow-up period.